‘One size will not fit all’ Differences between medical devices and pharmaceuticals: Consequences for the practice of HTA Chantale Lessard, BPharm, MSc, PhD, DcomplD Director, Health Economics, Policy & Reimbursement, Medical Affairs, Covidien, Medtronic Lecturer, Department of Health Administration, School of Public Health, University of Montreal
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
‘One size will not fit all’Differences between medical devices and pharmaceuticals: Consequences for the practice of HTA
Chantale Lessard, BPharm, MSc, PhD, DcomplDDirector, Health Economics, Policy & Reimbursement, Medical Affairs, Covidien, MedtronicLecturer, Department of Health Administration, School of Public Health, University of Montreal
CADTH Symposium 2015, Panel Session – Valuing Medical Technologies
2 | Medtronic Confidential
Main differences between medical devices and pharmaceuticals impacting on HTA
3 | Medtronic Confidential
Main differences between medical devices and pharmaceuticals impacting on HTA
4 | Medtronic Confidential
Main differences between medical devices and pharmaceuticals impacting on HTA
5 | Medtronic Confidential
Main differences between medical devices and pharmaceuticals impacting on HTA
6 | Medtronic Confidential
Consequences for the practice of HTA
• Recognition that a ‘one-size-fits-all’ approach to evaluation is inappropriate
• Evaluation approach should be tailored to the medical device• Based on the type, context of practice, indication, and use
• View the HTA for medical devices as an iterative process• Information about clinical efficacy and cost-effectiveness
is necessary but not sufficient– Understanding the social, ethical, professional and
organizational implications is also vital
• Development of innovative HTA methods for medical devices will require the engagement of industry, and of decision- and policy-makers